Breast Neoplasms Clinical Trial
Verified date | July 2015 |
Source | Intarcia Therapeutics |
Contact | n/a |
Is FDA regulated | No |
Health authority | United States: Food and Drug Administration |
Study type | Interventional |
The purpose of this study is to determine whether the first line combination hormonal therapy of an experimental drug, atamestane, plus an FDA-approved drug, toremifene (Fareston®), is more effective than another approved drug, letrozole (Femara®), in delaying the growth of breast cancer in postmenopausal patients with locally advanced or metastatic breast cancer, and whether the side effects of the combination are different from the side effects of letrozole.
Status | Completed |
Enrollment | 865 |
Est. completion date | January 2006 |
Est. primary completion date | January 2006 |
Accepts healthy volunteers | No |
Gender | Female |
Age group | 18 Years and older |
Eligibility |
Inclusion Criteria: - Women age 18 years or older - Pathological or histological confirmation of breast cancer at initial diagnosis or at the time of metastases - ECOG performance status of 0, 1 or 2 or Karnofsky performance status of 60 or higher - Predicted life expectancy of 12 weeks or more - Postmenopausal endocrine status. LH/FSH levels in the postmenopausal range in women whose menopause occurred less than 5 years ago - Locally recurrent, locally advanced, locally metastatic disease not amenable to radiation therapy or surgery and/or distant metastatic disease - At least one tumor localization measurable in 2 dimensions (one diameter at least 2 cm for soft tissue/visceral disease assessed by CT/MRI scan or conventional X-ray technique, one diameter at least 1 cm for bone lesions assessed by conventional X-ray techniques) - Estrogen receptor and/or progesterone receptor positive (by laboratory/institutional standard) at the time of initial diagnosis or determined during subsequent biopsy/surgery of metastases - Written informed consent obtained Exclusion Criteria: - Prior hormonal therapy to treat locally recurrent, locally advanced or metastatic disease - Prior adjuvant therapy with aromatase inhibitors or antiestrogens/SERMs within 12 months prior to enrollment - Progression of disease during therapy with antiestrogens (including SERMs administered for prevention of osteoporosis) - Life-threatening locally recurrent, locally advanced or metastatic disease or disease requiring chemotherapeutic intervention (such as inflammatory breast cancer) - History of known CNS metastases, significant neurological dysfunction including active seizures, or clinical signs of other significant neurological diseases - Other active malignancy (except basal cell carcinoma of the skin or in situ cervical cancer). Patients with previous malignancies must be without evidence of disease for at least five years - Renal insufficiency (serum creatinine > 2.0 mg/dL) - Aspartate aminotransferase, alanine aminotransferase or serum bilirubin levels more than 2.5 times upper limit of normal - Hemoglobin <9 g/dL - Platelet count of less than 100,000 platelets per mm3 - Total white blood cell count of less than 2,000 cells per mm3 - Premenopausal endocrine status; pregnant or lactating females - Usage of an investigational drug within the thirty (30) days prior to enrollment; or the planned usage of an investigational drug other than the study medication during the course of the current study - Contraindication to use of toremifene, atamestane, letrozole or any of the inactive components of their formulations - Prior enrollment in this study |
Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment
Country | Name | City | State |
---|---|---|---|
Canada | McGill University, Department of Oncology | Montreal | Quebec |
Canada | Ottawa Regional Cancer Centre | Ottawa | Ontario |
Canada | Northwestern Ontario Regional Cancer Centre | Thunder Bay | Ontario |
Canada | Princess Margaret Hospital | Toronto | Ontario |
Russian Federation | Arkhangelsk Regional Oncology Center, Department of Chemotherapy | Arkhangelsk | |
Russian Federation | Tatarstan Republican Clinical Oncology Center | Kazan | |
Russian Federation | Krasnodar Regional Clinical Oncology Center, Chemotherapy Department | Krasnodar | |
Russian Federation | Leningrad Regional Oncology Center | Leningrad | |
Russian Federation | Lipetsk Regional Oncology Center, Department of General Oncology | Lipetsk | |
Russian Federation | Blokhin Cancer Research Center, Department of Chemotherapy | Moscow | |
Russian Federation | Blokhin Cancer Research Center, Department of Chemotherapy and Combined Treatment of Tumors | Moscow | |
Russian Federation | Blokhin Cancer Research Center, Department of Clinical Pharmacology and Chemotherapy | Moscow | |
Russian Federation | Blokhin Cancer Research Center, Department of New Antitumor Drug Research | Moscow | |
Russian Federation | Central Clinical Hospital of the Ministry of Transport n.a. Semashko, Department of Chemotherapy | Moscow | |
Russian Federation | Hertzen Research Institute of Oncology, Department of Chemotherapy | Moscow | |
Russian Federation | Moscow City Hospital #40, Department of Chemotherapy | Moscow | |
Russian Federation | Moscow City Oncology Hospital #62 | Moscow | |
Russian Federation | Murmansk Regional Oncology Center | Murmansk | |
Russian Federation | Municipal Clinical Hospital #1, Department of Breast Tumors, Oncology Department | Novosibirsk | |
Russian Federation | Medical Radiological Research Center | Obninsk | |
Russian Federation | Ryazan Regional Clinical Oncology Center | Ryazan | |
Russian Federation | Samara Regional Oncology Center, Department of Chemotherapy | Samara | |
Russian Federation | Laboratory of Thoracic Oncology, St. Petersburg Pavlov State Medical University, Research Institute of Pulmonology | St. Petersburg | |
Russian Federation | Petrov Research Institute of Oncology, Department of Biotherapy and Bone Marrow Transplantation | St. Petersburg | |
Russian Federation | Petrov Research Institute of Oncology, Department of Breast Cancer | St. Petersburg | |
Russian Federation | Petrov Research Institute of Oncology, Department of Chemotherapy | St. Petersburg | |
Russian Federation | St. Petersburg City Oncology Center | St. Petersburg | |
Russian Federation | Stavropol Regional Oncology Center, Department of Chemotherapy | Stavropol | |
Russian Federation | Research Institute of Oncology, Tomsk Scientific Center, Siberian Department of the Russian Academy of Medical Sciences, Department of Chemotherapy | Tomsk | |
Russian Federation | V. Novgorod Regional Oncology Center, Department of Chemotherapy | V. Novgorod | |
Russian Federation | Burdenko Voronezh Medical Academy, Oncology Department, Clinical Facility: Regional Clinical Oncology Center | Voronezh | |
Ukraine | Cherkassy Regional Oncology Center, Chemotherapy Department | Cherkassy | |
Ukraine | Dnepropetrovsk State Medical Academy, Oncology Department. Clinical Facility: Dnepropetrovsk City Clinical Hospital #4 | Dnepropetrovsk | |
Ukraine | Donetsk State Medical University. Clinical Facility: Donetsk Regional Antineoplastic Center, Mammology Department | Donetsk | |
Ukraine | Ivano-Frankovsk State Medical Academy; Oncology Department Clinical Facility: Ivano-Frankovsk Regional Oncology Center | Ivano-Frankovsk | |
Ukraine | Kharkov Medical Academy of Postgraduate Education, Oncology and Pediatric Oncology Department. Clinical Facility: Kharkov Regional Clinical Oncology Dispensary, Chemotherapy Department | Kharkov | |
Ukraine | Kharkov State Medical University. Clinical Facility: Grigoriev Medical Radiology Institute, Chemotherapy Department | Kharkov | |
Ukraine | Kiev Central Clinical Hospital, Ukraine Security Services, Surgery Department | Kiev | |
Ukraine | Kiev Oncology Institute, Ukraine Medical Science Academy, Department of Breast Tumors | Kiev | |
Ukraine | Kiev Postgraduate Studies Medical Academy. Clinical Facility: Kiev City Oncology Hospital, Chemotherapy Department | Kiev | |
Ukraine | National Medical University, Oncology Department. Clinical Facility: Kiev City Oncology Hospital, Surgery Department | Kiev | |
Ukraine | Krivoy Rog City Oncology Center | Krivoy Rog | |
Ukraine | Lviv State Medical University, Oncology and Medical Radiology Department. Clinical Facility: Lviv State Oncology Regional Clinical Diagnostic Center, Chemotherapy Department | Lviv | |
Ukraine | Odessa State Medical University, Oncology Department. Clinical Facility: Odessa Regional Oncology Center, Chemotherapy Department | Odessa | |
Ukraine | Uzhgorod National University Oncology Course of Surgery Department of Postgraduate Education Faculty Clinical Facility: Zakarpatye Regional Oncology Center | Uzhgorod | |
Ukraine | Zaporozhye Statue Institute of Postgraduate Training. Oncology Department; Clinical Facility: Zaporozhye Regional Oncology Center | Zaporozhye | |
United States | Maryland Hematology/Oncology Associates | Baltimore | Maryland |
United States | Hematology Oncology Consultants, Inc. | Columbus | Ohio |
United States | Great Falls Clinic-Oncology West | Great Falls | Montana |
United States | California Cancer Care, Inc. | Greenbrae | California |
United States | Oncology Consultants | Houston | Texas |
United States | Kansas City Oncology and Hematology Group | Kansas City | Missouri |
United States | First Dynamic Healthcare Services, Inc. | Killeen | Texas |
United States | Midwest Internal Medicine, PLLC | Lake Havasu City | Arizona |
United States | Cache Valley Cancer Treatment & Research Clinic | Logan | Utah |
United States | Innovative Medical Research of South Florida Inc. | Miami Shores | Florida |
United States | Slocum-Dickson Medical Group | New Hartford | New York |
United States | Virginia Oncology Associates | Norfolk | Virginia |
United States | Western Washington Oncology Inc., P.S. | Olympia | Washington |
United States | Sharp Memorial Hospital | San Diego | California |
United States | Oncology Care Associates, PLLC | St. Joseph | Michigan |
United States | Georgia Cancer Specialists | Tucker | Georgia |
United States | Arizona Clinical Research Center | Tucson | Arizona |
Lead Sponsor | Collaborator |
---|---|
Intarcia Therapeutics |
United States, Canada, Russian Federation, Ukraine,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Time to tumor progression | time from randomization to first occurrence of tumor progression, assessed at week 12 and every subsequent 12 weeks for patients continuing in the study for up to approximately 36 months | No |
Status | Clinical Trial | Phase | |
---|---|---|---|
Enrolling by invitation |
NCT05558917 -
Comparison Between PECS BLOCK 2 vs ESP BLOCK in Ocnologic Breast Surgery
|
N/A | |
Active, not recruiting |
NCT03664778 -
Abbreviated Breast MRI After Cancer Treatment
|
||
Recruiting |
NCT03144622 -
18F-FSPG PET/CT Imaging in Patients With Cancers
|
||
Completed |
NCT05452499 -
Pain Neuroscience Education and Therapeutic Exercise as a Treatment for Breast Cancer Survivors Living With Sequelae
|
N/A | |
Active, not recruiting |
NCT04568902 -
Study of H3B-6545 in Japanese Women With Estrogen Receptor (ER)-Positive, Human Epidermal Growth Factor Receptor 2 (HER2)-Negative Breast Cancer
|
Phase 1 | |
Completed |
NCT02860585 -
Evaluation of Survival in Patients With Metastatic Breast Cancer Receiving High-dose Chemotherapy With Autologous Haematopoietic Stem Cell Transplantation
|
N/A | |
Completed |
NCT04059809 -
Photobiomodulation for Breast Cancer Radiodermatitis
|
Phase 2/Phase 3 | |
Recruiting |
NCT04557449 -
Study to Test the Safety and Tolerability of PF-07220060 in Participants With Advance Solid Tumors
|
Phase 1/Phase 2 | |
Completed |
NCT03698942 -
Delphinus SoftVueâ„¢ ROC Reader Study
|
||
Completed |
NCT00092950 -
Exercise in Women at Risk for Breast Cancer
|
Phase 2 | |
Terminated |
NCT04123704 -
Sitravatinib in Metastatic Breast Cancer
|
Phase 2 | |
Not yet recruiting |
NCT02151071 -
The Breast Surgery EnLight and LightPath Imaging System Study
|
Phase 1/Phase 2 | |
Recruiting |
NCT02934360 -
TR(ACE) Assay Clinical Specimen Study
|
N/A | |
Active, not recruiting |
NCT02950064 -
A Study to Determine the Safety of BTP-114 for Treatment in Patients With Advanced Solid Tumors With BRCA Mutations
|
Phase 1 | |
Not yet recruiting |
NCT02876848 -
A Novel E-Health Approach in Optimizing Treatment for Seniors (OPTIMUM Study)
|
N/A | |
Completed |
NCT02931552 -
Nuevo Amanecer II: Translating a Stress Management Program for Latinas
|
N/A | |
Recruiting |
NCT02547545 -
Breast Cancer Chemotherapy Risk Prediction Mathematical Model
|
N/A | |
Completed |
NCT02518477 -
Preventive Intervention Against Lymphedema After Breast Cancer Surgery
|
N/A | |
Completed |
NCT02303366 -
Pilot Study of Stereotactic Ablation for Oligometastatic Breast Neoplasia in Combination With the Anti-PD-1 Antibody MK-3475
|
Phase 1 | |
Completed |
NCT02652975 -
Anticancer Treatment of Breast Cancer Related to Cardiotoxicity and Dysfunctional Endothelium
|
N/A |